Combining Heavy Ion Radiation and Artificial MicroRNAs to Target the Homologous Recombination Repair Gene Efficiently Kills Human Tumor Cells

2013 ◽  
Vol 85 (2) ◽  
pp. 466-471 ◽  
Author(s):  
Zhiming Zheng ◽  
Ping Wang ◽  
Hongyan Wang ◽  
Xiangming Zhang ◽  
Minli Wang ◽  
...  
Keyword(s):  
Homologous Recombination ◽  
Tumor Cells ◽  
Human Tumor ◽  
Heavy Ion ◽  
Homologous Recombination Repair ◽  
Human Tumor Cells ◽  
Repair Gene ◽  
Recombination Repair ◽  
Heavy Ion Radiation

Research progress of PARP inhibitor monotherapy and combination therapy for endometrial cancer.

2021 ◽  
Vol 22 ◽  
Author(s):  
Ke Shen ◽  
Li Yang ◽  
Fei-Yan Li ◽  
Feng Zhang ◽  
Lei-Lei Ding ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Homologous Recombination ◽  
Tumor Cells ◽  
Checkpoint Inhibitors ◽  
Parp Inhibitor ◽  
Parp Inhibitors ◽  
Cell Cycle Checkpoint ◽  
Research Progress ◽  
Homologous Recombination Repair ◽  
Recombination Repair

: Endometrial cancer is one of the three most common malignant tumors in the female reproductive system. Advanced and recurrent endometrial cancers have poor prognoses and lack effective treatments. Poly(ADP-ribose) polymerase (PARP) inhibitors have been applied to many different types of tumors, and they can selectively kill tumor cells that are defective in homologous recombination repair. Endometrial cancer is characterized by mutations in homologous recombination repair genes; accordingly, PARP inhibitors have achieved positive results in off-label treatments of endometrial cancer cases. Clinical trials of PARP inhibitors as monotherapies and within combination therapies for endometrial cancer are ongoing. For this review, we searched PubMed with "endometrial cancer" and "PARP inhibitor" as keywords, and we used "olaparib", "rucaparib", "niraparib" and "talazoparib" as search terms in clinicaltrials.gov for ongoing trials. The literature search ended in October 2020, and only English-language publications were selected. Multiple studies confirm that PARP inhibitors play an important role in killing tumor cells with defects in homologous recombination repair. Its combination with immune checkpoint inhibitors, PI3K/AKT/mTOR pathway inhibitors, cell cycle checkpoint inhibitors, and other drugs can improve the treatment of endometrial cancer.

PD-0426: Homologous recombination repair deficient tumor cells exhibit increased radiosensitization by PARP inhibition

2014 ◽  
Vol 111 ◽  
pp. S170
Author(s):  
F. Hageman ◽  
C.V.M. Verhagen ◽  
A. Di Carli ◽  
M.J. O’Connor ◽  
J. Jonkers ◽  
...  
Keyword(s):  
Homologous Recombination ◽  
Tumor Cells ◽  
Parp Inhibition ◽  
Homologous Recombination Repair ◽  
Recombination Repair
Sign in / Sign up

Export Citation Format

Share Document